• WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 19.08.2020 | 18:26

RHÖN-KLINIKUM Aktiengesellschaft: Annual General Meeting resolves to retain net distributable profit - Dr. Jan Liersch elected in the constitutive meeting of the Supervisory Board as successor to its hitherto chairman Eugen Münch

DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): AGM/EGM/Personnel
19.08.2020 / 18:26
The issuer is solely responsible for the content of this announcement.


Corporate News

Bad Neustadt / Saale | 19th August 2020

RHÖN-KLINIKUM AG: Annual General Meeting resolves to retain net distributable profit - Dr. Jan Liersch elected in the constitutive meeting of the Supervisory Board as successor to its hitherto chairman Eugen Münch

  • Annual General Meeting resolves to retain net distributable profit due to ongoing uncertainties connected with COVID-19 pandemic
  • Dr. Jan Liersch elected after Annual General Meeting in constitutive Supervisory Board meeting as Chairman
  • Hitherto Chairman Eugen Münch leaves Supervisory Board due to age limit
  • Ordinary Annual General Meeting resolves to modify articles of association
At the ordinary Annual General Meeting (AGM) of RHÖN-KLINIKUM AG a large majority of shareholders was in favour of waiving a dividend for financial year 2019. They therefore followed the proposal by the Board of Management and Supervisory Board who had suggested to the AGM to carry forward the full net distributable profit of approx. Euro 203.5 million due to the ongoing uncertainties with regard to the further effects of the COVID-19 pandemic. Retaining the net distributable profit will strengthen the capital and liquidity base and safeguard the capability of RHÖN-KLINIKUM AG to make investments.

95.24 percent of the registered share capital was represented at the ordinary AGM of RHÖN-KLINIKUM AG which took place as a virtual general meeting without the physical presence of shareholders or their proxies pursuant to the law on measures to combat the effects of the COVID-19 pandemic from 27th March 2020.

Apart from the resolution on the appropriation of the net distributable profit, the agenda also included resolutions on the formal approval of the actions of the Board of Management and Supervisory Board for financial year 2019 and the election of new shareholder representatives onto the Supervisory Board as well as resolutions on modifying the articles of association and consent to group-internal corporate agreements. The amendments include provisions for Supervisory Board meetings to be held by telephone or video conference and for written votes to be cast. In addition, Supervisory Board compensation will be changed to a simpler, more transparent system with a reduced overall volume.

Apart from explaining the development of financial year 2019 and of the first six months of 2020, about which RHÖN-KLINIKUM AG has already reported in detail (see Corporate News dated 24th March 2020 and 6th August 2020), the Board of Management also spoke in its report about the strategic partnership with Asklepios and the determination of RHÖN-KLINIKUM AG in the fight against the COVID-19 pandemic.

Strong Partnership with Asklepios

The Board of Management welcomes the new partnership with Asklepios. With its five sites providing maximum and intermediate medical care RHÖN-KLINIKUM AG continues to remain a strong enterprise under the roof of the Asklepios Group. Both the medical and economic impetus of the new partnership will help RHÖN-KLINIKUM AG achieve its ambitious goals for the future in a rapidly changing political healthcare environment.

The university hospitals in Giessen and Marburg (UKGM) which have already been making a considerable contribution to the Company for many years must also retain their central position after the takeover.

Coping Well with COVID-19 Pandemic - Return to Normal Working Routine

Furthermore, the Board of Management also spoke of the determination of the Company and the dedication of its employees during the COVID-19 pandemic and thanked them for their dedicated commitment: "Now we wish - and should - return to our normal working routine as quickly as possible since it is our normal working routine where we are able to give all our patients - with COVID-19 or with other illnesses - our undivided attention and this must be our overall standard. It is a guiding principle which we never lost sight of at any of our five sites during the entire first wave of the COVID-19 pandemic."

Consistent Implementation of Digitalisation Strategy

Another focal point is the extensive digital transformation in the Company. The digitalisation of healthcare data, i.e. eliminating processes and documentation on paper, removing sectoral boundaries and actively making use of medical devices and sensors will in future be important focal points in the further development of the healthcare system which we at RHÖN wish to drive further forwards in a resolute manner together with Asklepios. All this will be accompanied by more out-patient medical services. The traditional out-patient and in-patient services and options will increasingly be augmented by telemedical services, not only as in-patient care but also in the patient's home environment.

New Representatives in the Supervisory Board - Company Founder Eugen Münch Highly Praised

Under Agenda Item No. 5 all eight members of the Supervisory Board who represent the shareholders were standing for election. The election of the eight new employee representatives had already taken place on 22nd July 2020.

Kai Hankeln, CEO of Asklepios Kliniken GmbH & Co. KGaA, was voted onto the Supervisory Board as a new member with a majority of 98.51 percent. The shareholders voted with a majority of 98.50 percent for Dr. Jan Liersch who was also standing as a candidate for the Chairman of the Supervisory Board. The Supervisory Board elected Dr. Jan Liersch immediately after the AGM in its constitutive meeting as its Chairman and successor to Eugen Münch who was leaving the Supervisory Board due to the age limit of 75 years which is stipulated in the articles of association and who was therefore not standing for re-election. However, he remains part of RHÖN-KLINIKUM AG in his new position as chief representative with full authorisation.

The Board of Management praised company founder, CEO of many years and hitherto Chairman of the Supervisory Board of RHÖN-KLINIKUM AG Eugen Münch: "His initiative and personal incentive both within the Company and externally are exemplary. He has shaped our Company and also the German hospital market with his visions like no other. He led RHÖN-KLINIKUM AG as the first private hospital corporate group onto the stock exchange, turned it into one of the largest healthcare providers in Germany and has now taken it with the strategic partnership with Asklepios into a new era of two strong partners standing for integrated modern healthcare in a digital network."

Dr. Julia Dannath-Schuh, Prof. Dr. Gerhard Ehninger, Irmtraut Gürkan, Nicole Mooljee Damani, Hafid Rifi and Christine Reißner were also voted onto the Supervisory Board. Following this election the Supervisory Board is now composed of the following members: Kai Hankeln, Dr. Jan Liersch, Dr. Julia Dannath-Schuh, Prof. Dr. Gerhard Ehninger, Irmtraut Gürkan, Nicole Mooljee Damani, Hafid Rifi, Christine Reißner, Dr. Thomas Pillukat, Georg Schulze-Ziehaus, Peter Berghöfer, Oliver Salomon, Regina Dickey, Peter Ducke, Prof. Dr. Eberhart Leopold and Dr. Martin Mandewirth.

You can find the detailed voting results for all 14 Agenda Items which included a resolution by the AGM on the website of RHÖN-KLINIKUM AG using the following link: https://www.rhoen-klinikum-ag.com/agm under the "Investor Relations" pull-down menu.


RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. The hospital group offers excellent medical care with a direct link to universities and research institutes. Over 860,000 patients are treated every year at the five group hospitals located in Bad Berka, Bad Neustadt, Frankfurt (Oder), Giessen and Marburg where more than 18,000 employees work. RHÖN-KLINIKUM AG is currently exploiting the opportunities available to develop new areas of growth. Entering the leading-edge telemedicine market with Medgate Deutschland, the innovative RHÖN campus concept for offering forward-looking healthcare across sectoral boundaries in rural areas as well as consistently extending our gradual corporate digitalisation are key pillars of the corporate strategy.

Further information:

Report by the Board of Management

Voting Results

More information under www.rhoen-klinikum-ag.com

Follow us:

Contact Persons:

RHÖN-KLINIKUM AG | Head of Corporate Communications and Marketing
Elke Pfeifer
Telephone: +49 9771 65-12110 | E-Mail: elke.pfeifer@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt
Telephone: +49 9771 65-12250 | E-Mail: julian.schmitt@rhoen-klinikum-ag.com

RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt / Saale, Germany

19.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Unternehmen im Fokus

Wasserstoff-Rendite mit HPS

Spätestens mit Veröffentlichung der nationalen Wasserstoffstrategie rücken sämtliche „Wasserstoff-Unternehmen“ verstärkt in den Fokus der Investoren.
Das in Berlin ansässige Unternehmen HPS Home Power Solutions setzt Wasserstoff als saisonales Speichermedium für das autarke und vollständig CO2-freie Energieversorgungssystem picea® in Ein- bis Zweifamilienhäusern ein.
Dieses weltweit erste Solar-Wasserstoffkraftwerk für zuhause erlaubt mit einer Solaranlage eine dezentrale vollständige Stromversorgung über das gesamte Jahr und unterstützt dabei sogar zusätzlich die Wärmeversorgung im Haus.
Zur Finanzierung des laufenden Markteintritts und des weiteren Wachstums begibt HPS ein Nachrangdarlehen von bis zu 4 Mio. € über die Plattform GLS Crowd und verzinst das eingeworbene Kapital ab einem Einsatz von 250 € mit 7 % über eine Laufzeit von 5 Jahren. Die Zeichnungsfrist beginnt am 03.11.2020 um 10:30 Uhr.

Hinweis gemäß § 12 Abs. 2 Vermögensanlagengesetz: Der Erwerb dieser Vermögensanlage ist mit erheblichen Risiken verbunden und kann zum vollständigen Verlust des eingesetzten Vermögens führen.

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.


Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Continental AG: Dr. Elmar Degenhart legt sein Amt als Vorstandsvorsitzender von Continental aus eigenem Entschluss vorzeitig nieder

29. Oktober 2020, 21:05

Aktueller Webcast


9M 2020 Analyst Call

10. November 2020

Aktuelle Research-Studie

CLIQ Digital AG

Original-Research: CLIQ Digital AG (von Montega AG): Kaufen

29. Oktober 2020